Drug discovery is adapting to novel technologies such as data science, informatics, and
artificial intelligence (AI) to accelerate effective treatment development while reducing costs …

There are∼ 4500 genes within the 'druggable genome', the subset of the human genome
that expresses proteins able to bind drug-like molecules, yet existing drugs only target a few …

Abstract The Illuminating the Druggable Genome (IDG) project aims to improve our
understanding of understudied proteins and our ability to study them in the context of …

Biological networks are often used to represent complex biological systems, which can
contain several types of entities. Analysis and visualization of such networks is supported by …

Various post-translational modifications (PTMs) participate in nearly all aspects of biological
processes by regulating protein functions, and aberrant states of PTMs are frequently …

Background Birth defects are functional and structural abnormalities that impact about 1 in
33 births in the United States. They have been attributed to genetic and other factors such as …

Progressive neurocognitive dysfunction is the leading cause of a reduced quality of life in
patients with primary brain tumors. Understanding how the human brain responds to cancer …

Mutations in cancer risk genes increase susceptibility, but not all carriers develop cancer.
Indeed, while DNA mutations are necessary drivers of cancer, only a small subset of …

PCPE-2 was discovered at the beginning of this century, and was soon identified as a close
homolog of PCPE-1 (procollagen C-proteinase enhancer 1). After the demonstration that it …

The Knowledge Management Center (KMC) for the Illuminating the Druggable Genome
(IDG) project aims to aggregate, update, and articulate protein-centric data knowledge for …